Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Longitudinal Adverse Event Assessment of the Combination of Ipilimumab, Nivolumab and Brentuximab Vedotin in Relapsed / Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412: Arms A-F)

Fangxin Hong, PhD, Gita Thanarajasingam, MD, Stephen M. Ansell, MD PhD, Richard F Ambinder, MD, Jonathon B. Cohen, MDMS, Michael Robertson, MD, Kevin A. David, MD, Ranjana H Advani, MD, Timothy S. Fenske, MD, Stefan Klaus Barta, MDMRCP,MS, Neil Palmisiano, MD, Jakub Svoboda, MD, David Morgan, MD, Reem Karmali, MD, Thomas E. Witzig, MD, Amylou C. Dueck, PhD, Paul Novotny, Brad S Kahl, MD, Catherine Diefenbach, MD

Blood (2018) 132 (Supplement 1): 623.

https://doi.org/10.1182/blood-2018-99-119372

Published: 2018

Journal Articles

A Phase I Study with an Expansion Cohort of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Research Group (E4412: Arms G-I)

Catherine Diefenbach, MD, Fangxin Hong, PhD, Richard F Ambinder, MD, Jonathon B. Cohen, MDMS, Michael Robertson, MD, Kevin A. David, MD, Ranjana H. Advani, MD, Timothy S. Fenske, MD, Stefan Klaus Barta, MDMRCP,MS, Neil Palmisano, MD, Jakub Svoboda, MD, David Morgan, MD, Reem Karmali, MD, Brad S Kahl, MD, Stephen M. Ansell, MD PhD

Blood (2018) 132 (Supplement 1): 679.

https://doi.org/10.1182/blood-2018-99-115390

Published: 2018

Journal Articles

Title: A Phase I Study with an Expansion Cohort of the Combination of Ipilimumab and Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412 Arms D and E)

Catherine S. Diefenbach, MD, Fangxin Hong, PhD, Kevin A David, MD, Jonathon Cohen, Michael Robertson, MD, Ranjana Advani, MD, Neil D. Palmisiano, MD, Richard F. Ambinder, MD PhD, Brad S Kahl, Stephen Ansell, MD PhD

Blood (2016) 128 (22): 1106.

https://doi.org/10.1182/blood.V128.22.1106.1106

Published: 2016

Journal Articles

The Outcome of the Combination of Tacrolimus, Sirolimus, and ATG for GvHD Prophylaxis on Allogeneic Stem Cell Transplantation From Matched Unrelated Donors

Yaser Homsi, MD, Dareen Alwan, MD, Patrick Kiel, PharmD, Lindsay Rosenbeck, PharnD, Srivastava Shivani, MD, Jennifer E. Schwartz, MD, FRCP(C), Robert P. Nelson, Jr., MD, Rafat Abonour, MD, Michael Robertson, MD, Sherif Farag, MD, PhD, FRACP, FRCPA

Blood (2010) 116 (21): 2345.

https://doi.org/10.1182/blood.V116.21.2345.2345

Published: 2010

Journal Articles

Costimulatory Effects of Interleukin-18 (IL-18) on Human Natural Killer (NK) Cells Activated through Fc Receptors for Immunoglobulin (IgG)

Shivani Srivastava, MD, Hailin Feng, Menggang Yu, PhD, David Pelloso, Michael Robertson, MD

Blood (2010) 116 (21): 2780.

https://doi.org/10.1182/blood.V116.21.2780.2780

Published: 2010

Journal Articles

Infusion of Large Number of Circulating Myeloma Cells Does Not Influence the Survival of Patients Undergoing Autologous Stem Cell Transplantation.

Rafat Abonour, Hayley Knollman, Attaya Suvannasankha, MD, Menggang Yu, Rebecca Britton, Shivani Srivastava, MD, Robert P. Nelson, Jr., MD, Jennifer E. Schwartz, MD, FRCP(C), Michael Robertson, MD, Kenneth Cornetta, MD, Sherif Farag, MBBS, PhD

Blood (2009) 114 (22): 1224.

https://doi.org/10.1182/blood.V114.22.1224.1224

Published: 2009

Journal Articles

A Phase I Trial of High-Dose Clofarabine, Etoposide, and Cyclophosphamide: A Novel Preparative Regimen Prior to Autologous Peripheral Blood Stem Cell (PBSC) Transplantation in Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma.

Sherif Farag, MD, PhD, Lisa L Wood, RN, Shivani Srivastava, MD, Robert P. Nelson, Jr., MD, Jennifer E. Schwartz, MD, FRCP(C), Elizabeth Cox, Rafat Abonour, MD, Michael Robertson, MD,

Blood (2009) 114 (22): 3402.

https://doi.org/10.1182/blood.V114.22.3402.3402

Published: 2009

Journal Articles

Phase I Trial of High-Dose Clofarabine and Busulfan as a Myeloablative Regimen Prior to Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory Acute Leukemia.

Sherif Farag, MD, PhD, Lisa L Wood, RN, Jennifer E. Schwartz, MD, FRCP(C), Shivani Srivastava, MD, Robert P. Nelson, Jr., MD, Michael Robertson, MD, Rafat Abonour, MD, Hamid Sayar, MD, Larry D. Cripe, MD

Blood (2009) 114 (22): 198.

https://doi.org/10.1182/blood.V114.22.198.198

Published: 2009

Journal Articles

A Placebo-Controlled Phase III Trial of Patient-Specific Immunotherapy with Mitumprotimut-T (ID-KLH) and GM-CSF Following Rituximab in Patients with CD20+ Follicular Lymphoma

Arnold S. Freedman, MD, Sattva Neelapu, MD, Craig R Nichols, MD, Michael Robertson, MD, Benjamin Djulbegovic, MD, PhD, Jane N. Winter, MD, Daniel Gold, PhD, John Bender, PharmD, Morgan Stewart, PhD, Richard G. Ghalie, MD, MBA, Paul A. Hamlin, Jr., MD

Blood (2008) 112 (11): 236.

https://doi.org/10.1182/blood.V112.11.236.236

Published: 2008

Journal Articles

Phase III Trial of Active Immunotherapy (FavId®, Id/KLH) Following Rituximab Induction Therapy: Clinical Responses in Patients (pts) with Follicular Non-Hodgkin’s Lymphoma (fNHL).

Arnold S. Freedman, MD, Paul A. Hamlin, MD, Sattva Neelapu, MD, Craig Nichols, MD, Michael Robertson, MD, Gregoire Bergier, MD, Jane N. Winter, MD, Jonathan Polikoff, MD, Thomas Lin, MD, PhD, Brad Pohlman, MD, Vanessa Esquibel, Teresa Melink, NP, John Bender, PharmD

Blood (2006) 108 (11): 2756.

https://doi.org/10.1182/blood.V108.11.2756.2756

Published: 2006

NARROW

Longitudinal Adverse Event Assessment of the Combination of Ipilimumab, Nivolumab and Brentuximab Vedotin in Relapsed / Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412: Arms A-F)

A Phase I Study with an Expansion Cohort of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Research Group (E4412: Arms G-I)

Title: A Phase I Study with an Expansion Cohort of the Combination of Ipilimumab and Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412 Arms D and E)

The Outcome of the Combination of Tacrolimus, Sirolimus, and ATG for GvHD Prophylaxis on Allogeneic Stem Cell Transplantation From Matched Unrelated Donors

Costimulatory Effects of Interleukin-18 (IL-18) on Human Natural Killer (NK) Cells Activated through Fc Receptors for Immunoglobulin (IgG)

Infusion of Large Number of Circulating Myeloma Cells Does Not Influence the Survival of Patients Undergoing Autologous Stem Cell Transplantation.

A Phase I Trial of High-Dose Clofarabine, Etoposide, and Cyclophosphamide: A Novel Preparative Regimen Prior to Autologous Peripheral Blood Stem Cell (PBSC) Transplantation in Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma.

Phase I Trial of High-Dose Clofarabine and Busulfan as a Myeloablative Regimen Prior to Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory Acute Leukemia.

A Placebo-Controlled Phase III Trial of Patient-Specific Immunotherapy with Mitumprotimut-T (ID-KLH) and GM-CSF Following Rituximab in Patients with CD20+ Follicular Lymphoma

Phase III Trial of Active Immunotherapy (FavId®, Id/KLH) Following Rituximab Induction Therapy: Clinical Responses in Patients (pts) with Follicular Non-Hodgkin’s Lymphoma (fNHL).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only